(Q36852254)

16 August 2017

Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells (English)

1 reference

16 August 2017

1 reference

1 reference

6

Gabriel N Hortobagyi

1 reference

16 August 2017

2

Ashutosh Pal

1 reference

16 August 2017

Dongwei Zhang

1

1 reference

16 August 2017

William G Bornmann

3

1 reference

16 August 2017

Fumiyuki Yamasaki

4

1 reference

16 August 2017

Francisco J Esteva

5

1 reference

16 August 2017

Chandra Bartholomeusz

7

1 reference

16 August 2017

Naoto T Ueno

8

1 reference

16 August 2017

1 July 2008

1 reference

Molecular Cancer Therapeutics

16 August 2017

1 reference

16 August 2017

7

1 reference

16 August 2017

1846-1850

1 reference

16 August 2017

7

1 reference

Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity

16 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2525738

Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2525738

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2525738

Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2525738

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2525738

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2525738

The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2525738

The ErbB signaling network: receptor heterodimerization in development and cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2525738

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2525738

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2525738

Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2525738

Epidermal growth factor receptor in human breast cancer comparison with steroid receptors and other prognostic factors

27 June 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18644997

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Prospective study of the prognostic significance of epidermal growth factor receptor in primary breast cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18644997

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1158/1535-7163.MCT-08-0168

1 reference

16 August 2017

1 reference

16 August 2017

1 reference